Clinical Trial Update: Multicenter Study Evaluating 12 Versus 24 Weeks Therapy With Peginterferon and Ribavirin for Hepatitis C Virus (HCV) Genotype 2 or 3 [Phase 4]

View source ↗

Summary

A multicenter Phase 4 study comparing 12 weeks versus 24 weeks of pegylated interferon plus ribavirin in hepatitis C with genotypes 2 or 3 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Pegasys (pegylated interferon alfa-2a)
• Ribavirin (ribavirin)

Snippet

Sponsor: NORDynamIC Study Group | Conditions: Hepatitis C Virus | Phase 4 | Status: COMPLETED